Expression and clinicopathological significance of EED, SUZ12 and EZH2 mRNA in colorectal cancer

Journal of Cancer Research and Clinical Oncology

Volumn 141, Issue 4, 2015, Pages 661-669

  Liu, Yan Long ^a   Gao, Xu ^a   Jiang, Yang ^a   Zhang, Gan ^a   Sun, Zi Cheng ^b   Cui, Bin Bin ^a   Yang, Yan Mei ^a  

^a HARBIN MEDICAL UNIVERSITY   (China)

^b Department of Liver Gallbladder Surgery The First People s Hospital   (China)

Author keywords

Colorectal cancer; EED; EZH2; SUZ12

Indexed keywords

EMBRYONIC ECTODERM DEVELOPMENT PROTEIN; MESSENGER RNA; SUPPRESSOR OF ZESTE 12 HOMOLOG PROTEIN; TRANSCRIPTION FACTOR EZH2; UNCLASSIFIED DRUG; EED PROTEIN, HUMAN; EZH2 PROTEIN, HUMAN; POLYCOMB REPRESSIVE COMPLEX 2; SUZ12 PROTEIN, HUMAN;

ARTICLE; CANCER PROGNOSIS; CANCER SIZE; CANCER STAGING; CANCER SURVIVAL; CANCER TISSUE; CARCINOGENESIS; COLORECTAL CANCER; DISEASE FREE SURVIVAL; DISTANT METASTASIS; GENE EXPRESSION; HUMAN; HUMAN TISSUE; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RISK FACTOR; UPREGULATION; WESTERN BLOTTING; COLORECTAL TUMOR; DISEASE COURSE; GENE EXPRESSION REGULATION; GENETICS; KAPLAN MEIER METHOD; METABOLISM; MULTIVARIATE ANALYSIS; PATHOLOGY; PROGNOSIS;

BLOTTING, WESTERN; COLORECTAL NEOPLASMS; DISEASE PROGRESSION; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; KAPLAN-MEIER ESTIMATE; LYMPHATIC METASTASIS; MULTIVARIATE ANALYSIS; NEOPLASM STAGING; POLYCOMB REPRESSIVE COMPLEX 2; PROGNOSIS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER;

EID: 84925488524     PISSN: 01715216     EISSN: 14321335     Source Type: Journal    
DOI: 10.1007/s00432-014-1854-5     Document Type: Article

References (48)

1. Balasubramanian S, Lee K, Adhikary G, Gopalakrishnan R, Rorke EA, Eckert RL (2008) The Bmi-1 polycomb group gene in skin cancer: regulation of function by (-)-epigallocatechin-3-gallate. Nutr Rev 66(Suppl 1):S65–S68. doi:10.1111/j.1753-4887.2008.00071.x
2. Brait M, Sidransky D (2011) Cancer epigenetics: above and beyond. Toxicol Mech Methods 21:275–288. doi:10.3109/15376516.2011.562671
3. Bryant RJ, Cross NA, Eaton CL, Hamdy FC, Cunliffe VT (2007) EZH2 promotes proliferation and invasiveness of prostate cancer cells. Prostate 67:547–556. doi:10.1002/pros.20550
4. Cao R, Zhang Y (2004) SUZ12 is required for both the histone methyltransferase activity and the silencing function of the EED-EZH2 complex. Mol Cell 15:57–67. doi:10.1016/j.molcel.2004.06.020
5. Cao R et al (2002) Role of histone H3 lysine 27 methylation in Polycomb-group silencing. Science 298:1039–1043. doi:10.1126/science.1076997
6. Cao W et al (2011) EZH2 promotes malignant phenotypes and is a predictor of oral cancer development in patients with oral leukoplakia. Cancer Prev Res 4:1816–1824. doi:10.1158/1940-6207.CAPR-11-0130
7. Cao W et al (2012) EZH2 promotes malignant behaviors via cell cycle dysregulation and its mRNA level associates with prognosis of patient with non-small cell lung cancer. PLoS ONE 7:e52984. doi:10.1371/journal.pone.0052984
8. Cui B, Tao J, Yang Y (2012) Studies on the expression patterns of class I PI3K catalytic subunits and its prognostic significance in colorectal cancer. Cell Biochem Biophys 62:47–54. doi:10.1007/s12013-011-9257-6
9. Cui Y, Chen J, He Z, Xiao Y (2013) SUZ12 depletion suppresses the proliferation of gastric cancer cells. Cell Physiol Biochem 31:778–784. doi:10.1159/000350095
10. Denisenko O, Shnyreva M, Suzuki H, Bomsztyk K (1998) Point mutations in the WD40 domain of Eed block its interaction with Ezh2. Mol Cell Biol 18:5634–5642
11. Eskander RN, Ji T, Huynh B, Wardeh R, Randall LM, Hoang B (2013) Inhibition of enhancer of zeste homolog 2 (EZH2) expression is associated with decreased tumor cell proliferation, migration, and invasion in endometrial cancer cell lines. Int J Gynecol Cancer 23:997–1005. doi:10.1097/IGC.0b013e318296a265
12. Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM (2010) Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer 127:2893–2917. doi:10.1002/ijc.25516
13. Fluge O et al (2009) Expression of EZH2 and Ki-67 in colorectal cancer and associations with treatment response and prognosis. Br J Cancer 101:1282–1289. doi:10.1038/sj.bjc.6605333
14. Fussbroich B et al (2011) EZH2 depletion blocks the proliferation of colon cancer cells. PLoS ONE 6:e21651. doi:10.1371/journal.pone.0021651
15. Gong Y et al (2011) Polycomb group protein EZH2 is frequently expressed in inflammatory breast cancer and is predictive of worse clinical outcome. Cancer 117:5476–5484. doi:10.1002/cncr.26179
16. Hammoud SS, Cairns BR, Jones DA (2013) Epigenetic regulation of colon cancer and intestinal stem cells. Curr Opin Cell Biol 25:177–183. doi:10.1016/j.ceb.2013.01.007
17. Hu S et al (2010) Overexpression of EZH2 contributes to acquired cisplatin resistance in ovarian cancer cells in vitro and in vivo. Cancer Biol Ther 10:788–795
18. Iliopoulos D, Lindahl-Allen M, Polytarchou C, Hirsch HA, Tsichlis PN, Struhl K (2010) Loss of miR-200 inhibition of Suz12 leads to polycomb-mediated repression required for the formation and maintenance of cancer stem cells. Mol Cell 39:761–772. doi:10.1016/j.molcel.2010.08.013
19. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D (2011) Global cancer statistics. CA Cancer J Clin 61:69–90. doi:10.3322/caac.20107
20. Jones PA, Baylin SB (2007) The epigenomics of cancer. Cell 128:683–692. doi:10.1016/j.cell.2007.01.029
21. Khare S, Verma M (2012) Epigenetics of colon cancer. Methods Mol Biol 863:177–185. doi:10.1007/978-1-61779-612-8_10
22. Kim JH et al (2004) The Bmi-1 oncoprotein is overexpressed in human colorectal cancer and correlates with the reduced p16INK4a/p14ARF proteins. Cancer Lett 203:217–224
23. Kim W, Bird GH, Neff T, Guo G, Kerenyi MA, Walensky LD, Orkin SH (2013) Targeted disruption of the EZH2-EED complex inhibits EZH2-dependent cancer. Nat Chem Biol 9:643–650. doi:10.1038/nchembio.1331
24. Kodach LL et al (2010) The role of EZH2 and DNA methylation in the silencing of the tumour suppressor RUNX3 in colorectal cancer. Carcinogenesis 31:1567–1575. doi:10.1093/carcin/bgq147
25. Ku M et al (2008) Genomewide analysis of PRC1 and PRC2 occupancy identifies two classes of bivalent domains. PLoS Genet 4:e1000242. doi:10.1371/journal.pgen.1000242
26. Li DW et al (2010) Expression level of Bmi-1 oncoprotein is associated with progression and prognosis in colon cancer. J Cancer Res Clin Oncol 136:997–1006. doi:10.1007/s00432-009-0745-7
27. Li H et al (2012) SUZ12 promotes human epithelial ovarian cancer by suppressing apoptosis via silencing HRK. Mol Cancer Res 10:1462–1472. doi:10.1158/1541-7786.MCR-12-0335
28. Lin YW, Chen HM, Fang JY (2011) Gene silencing by the Polycomb group proteins and associations with cancer. Cancer Invest 29:187–195. doi:10.3109/07357907.2010.512605
29. Liu C, Shi X, Wang L, Wu Y, Jin F, Bai C, Song Y (2014) SUZ12 is involved in progression of non-small cell lung cancer by promoting cell proliferation and metastasis. Tumour Biol 35:6073–6082. doi:10.1007/s13277-014-1804-5
30. Martin-Perez D et al (2010) Deregulated expression of the polycomb-group protein SUZ12 target genes characterizes mantle cell lymphoma. Am J Pathol 177:930–942. doi:10.2353/ajpath.2010.090769
31. Novak K (2004) Epigenetics changes in cancer cells. MedGenMed 6:17
32. Pietersen AM et al (2008) EZH2 and BMI1 inversely correlate with prognosis and TP53 mutation in breast cancer. Breast Cancer Res 10:R109. doi:10.1186/bcr2214
33. Piunti A, Pasini D (2011) Epigenetic factors in cancer development: polycomb group proteins. Future Oncol 7:57–75. doi:10.2217/fon.10.157
34. Richly H, Aloia L, Di Croce L (2011) Roles of the Polycomb group proteins in stem cells and cancer. Cell Death Dis 2:e204. doi:10.1038/cddis.2011.84
35. Rodenhiser DI (2009) Epigenetic contributions to cancer metastasis. Clin Exp Metastasis 26:5–18. doi:10.1007/s10585-008-9166-2
36. Sato T et al (2013) PRC2 overexpression and PRC2-target gene repression relating to poorer prognosis in small cell lung cancer. Sci Rep 3:1911. doi:10.1038/srep01911
37. Seo GS et al (2013) EED gene polymorphism in patients with colorectal cancer. Int J Biol Markers 28:274–279. doi:10.5301/JBM.5000024
38. Sharma S, Kelly TK, Jones PA (2010) Epigenetics in cancer. Carcinogenesis 31:27–36. doi:10.1093/carcin/bgp220
39. Shen L, Cui J, Liang S, Pang Y, Liu P (2013) Update of research on the role of EZH2 in cancer progression. Onco Targets Ther 6:321–324. doi:10.2147/OTT.S42453
40. Simon JA, Lange CA (2008) Roles of the EZH2 histone methyltransferase in cancer epigenetics. Mutat Res 647:21–29. doi:10.1016/j.mrfmmm.2008.07.010
41. Sparmann A, van Lohuizen M (2006) Polycomb silencers control cell fate, development and cancer. Nat Rev Cancer 6:846–856. doi:10.1038/nrc1991
42. Tan JZ, Yan Y, Wang XX, Jiang Y, Xu HE (2014) EZH2: biology, disease, and structure-based drug discovery. Acta Pharmacol Sin 35:161–174. doi:10.1038/aps.2013.161
43. Wang CG, Ye YJ, Yuan J, Liu FF, Zhang H, Wang S (2010) EZH2 and STAT6 expression profiles are correlated with colorectal cancer stage and prognosis. World J Gastroenterol 16:2421–2427
44. Wang J, Ma ZB, Li K, Guo GH (2014) Association between EZH2 polymorphisms and colorectal cancer risk in Han Chinese population. Med Oncol 31:874. doi:10.1007/s12032-014-0874-y
45. Wolters T, Vissers KJ, Bangma CH, Schroder FH, van Leenders GJ (2010) The value of EZH2, p27(kip1), BMI-1 and MIB-1 on biopsy specimens with low-risk prostate cancer in selecting men with significant prostate cancer at prostatectomy. BJU Int 106:280–286. doi:10.1111/j.1464-410X.2009.08998.x
46. Yin T et al (2011) Bmi-1 promotes the chemoresistance, invasion and tumorigenesis of pancreatic cancer cells. Chemotherapy 57:488–496. doi:10.1159/000334103
47. Yoo KH, Hennighausen L (2012) EZH2 methyltransferase and H3K27 methylation in breast cancer. Int J Biol Sci 8:59–65
48. Yu H et al (2012) PRC2/EED-EZH2 complex is up-regulated in breast cancer lymph node metastasis compared to primary tumor and correlates with tumor proliferation in situ. PLoS ONE 7:e51239. doi:10.1371/journal.pone.0051239